Tweet
Euro Surveill. 2010-2011 INFLUENZA SEASONAL VACCINE, PRELIMINARY MID-SEASON EFFECTIVENESS ESTIMATES: REASON FOR CONCERN, CONFOUNDING OR ARE WE FOLLOWING THE RIGHT TRACK?
2010-2011 INFLUENZA SEASONAL VACCINE, PRELIMINARY MID-SEASON EFFECTIVENESS ESTIMATES: REASON FOR CONCERN, CONFOUNDING OR ARE WE FOLLOWING THE RIGHT TRACK?
[Source: Eurosurveillance, full text: (LINK). Extract, edited.]
Eurosurveillance, Volume 16, Issue 11, 17 March 2011
Editorials
2010-2011 INFLUENZA SEASONAL VACCINE, PRELIMINARY MID-SEASON EFFECTIVENESS ESTIMATES: REASON FOR CONCERN, CONFOUNDING OR ARE WE FOLLOWING THE RIGHT TRACK?
J Puig-Barber? 1
(1) Vaccines Research Unit, Centre for Public Health Research, Valencia, Spain
Citation style for this article: Puig-Barber? J. 2010-2011 influenza seasonal vaccine, preliminary mid- season effectiveness estimates: reason for concern, confounding or are we following the right track?. Euro Surveill. 2011;16(11):pii=19821. Available online: http://www.eurosurveillance.org/View...rticleId=19821
Date of submission: 14 March 2011
During the last 10 years there have been major advances in influenza surveillance, vaccine production and methods to determine vaccine effectiveness (VE), influenza diagnosis by real-time polymerase chain reaction (PCR), and influenza virology. Most of these have been fostered by the threat of a possible pandemic and the planning efforts devoted to minimising its impact.
The Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) network, funded by the European Centre for Disease Prevention and Control (ECDC), has made a substantial contribution to these efforts. Among other activities, it has endorsed,case?control test-negative studies focused on providing VE estimates for specific laboratory-confirmed influenza outcomes, especially medically attended influenza-like illness (ILI) [1-3]. As a result of this initiative, I-MOVE associates have published preliminary mid-season estimates of the VE of the 2010/11 influenza seasonal trivalent vaccine to prevent cases of medically attended ILI laboratory-confirmed for influenza [4,5]: two additional preliminary reports are published in this week?s issue of Eurosurveillance [6,7].
(...)
-
------
[Source: Eurosurveillance, full text: (LINK). Extract, edited.]
Eurosurveillance, Volume 16, Issue 11, 17 March 2011
Editorials
2010-2011 INFLUENZA SEASONAL VACCINE, PRELIMINARY MID-SEASON EFFECTIVENESS ESTIMATES: REASON FOR CONCERN, CONFOUNDING OR ARE WE FOLLOWING THE RIGHT TRACK?
J Puig-Barber? 1
(1) Vaccines Research Unit, Centre for Public Health Research, Valencia, Spain
Citation style for this article: Puig-Barber? J. 2010-2011 influenza seasonal vaccine, preliminary mid- season effectiveness estimates: reason for concern, confounding or are we following the right track?. Euro Surveill. 2011;16(11):pii=19821. Available online: http://www.eurosurveillance.org/View...rticleId=19821
Date of submission: 14 March 2011
During the last 10 years there have been major advances in influenza surveillance, vaccine production and methods to determine vaccine effectiveness (VE), influenza diagnosis by real-time polymerase chain reaction (PCR), and influenza virology. Most of these have been fostered by the threat of a possible pandemic and the planning efforts devoted to minimising its impact.
The Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) network, funded by the European Centre for Disease Prevention and Control (ECDC), has made a substantial contribution to these efforts. Among other activities, it has endorsed,case?control test-negative studies focused on providing VE estimates for specific laboratory-confirmed influenza outcomes, especially medically attended influenza-like illness (ILI) [1-3]. As a result of this initiative, I-MOVE associates have published preliminary mid-season estimates of the VE of the 2010/11 influenza seasonal trivalent vaccine to prevent cases of medically attended ILI laboratory-confirmed for influenza [4,5]: two additional preliminary reports are published in this week?s issue of Eurosurveillance [6,7].
(...)
-
------